Benitec Biopharma Inc. (BNTC) News
Filter BNTC News Items
BNTC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BNTC News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest BNTC News From Around the Web
Below are the latest news stories about BENITEC BIOPHARMA INC that investors may wish to consider to help them evaluate BNTC as an investment opportunity.
Hedge funds investors own a significant stake of 38% in Benitec Biopharma Inc. (NASDAQ:BNTC)Key Insights Given the large stake in the stock by institutions, Benitec Biopharma's stock price might be vulnerable to... |
Benitec Biopharma initiated with a Buy at H.C. WainwrightH.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Benitec Biopharma (BNTC) with a Buy rating and $28 price target Benitec is a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference platform, the analyst tells investors in a research note. The firm says initial clinical findings “appear encouraging, with strong mechanistic rationale for therapeutic impact.” Publishe |
Wall Street Analysts See an 113.71% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 113.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's WhyBenitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
Benitec Biopharma to Participate in Upcoming Investor Conferences in DecemberHAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming investor conferences. Piper Sandler Annual Healthcare ConferenceDate: December 4, 2024Time of Fireside |
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update-Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in October as a Late-Breaking Oral Presentation at the 29th Annual Congress of the World Muscle Society- -Third Subject Safely Treated with the Low-Dose of BB-301 in October 2024, and Fourth Subject Expected to Receive Treatment with the Low-Dose of BB-301 in December 20 |
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare ConferenceHAYWARD, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announces CEO Jerel A. Banks, M.D., Ph.D. will be participating in the Guggenheim Securities Healthcare Conference, taking place in Boston from November 11-13, 2024. Date: November |
Benitec Biopharma Announces Updated Investor Webcast Information-Management plans to host an investor webcast on October 14th at 8:30 am EDT to provide an update for the BB-301 Phase 1b/2a Clinical Study, details below- -The webcast access information has been revised from the conference call information provided on October 12th- HAYWARD, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprie |
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Questionnaire Score Representative of Clinically Normal Swallowing- -Management plans to host a conference call on October 14 at 8:30 am EDT to discuss the interim results, details below- HAYWARD, Calif., Oct. 12, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”) |
Suvretta Capital Management's Strategic Acquisition in Benitec Biopharma IncOn September 26, 2024, Suvretta Capital Management, LLC made a significant addition to its investment portfolio by acquiring 8,829,053 shares of Benitec Biopharma Inc (NASDAQ:BNTC). This transaction, executed at a price of $8.79 per share, marks a notable increase in the firm's stake in the biotechnology company, reflecting a strategic move within the healthcare sector. The acquisition not only increased the firm's total shares in Benitec Biopharma but also raised its portfolio position to 2.79%, with a substantial impact of 2.25%. |